BEIJING, March 18 (Xinhua) -- Shanghai Henlius Biotech, Inc. (2696.HK), a biopharmaceutical company in east China's Shanghai, announced on Wednesday that its annual revenue in 2021 reached around 1.68 billion yuan (about 265.04 million U.S. dollars), up 186.3 percent year on year, reported China Securities Journal on Thursday.
The company has been striving to provide innovative products that are both qualified and affordable to patients across the globe. With four products launched in China and one in Europe covering oncology, autoimmune diseases, ophthalmic diseases, etc., the company has benefited over 170,000 patients around the world.
In addition to promoting its products in the global market, the company has also been strengthening its innovation potentials based on the unmet clinical needs. With R&D input reaching around 1.76 billion yuan in 2021, the company has seen significant clinical progress in 12 projects and received international clinical approvals for six products and one combination therapy, according to the announcement.
Up until now, Henlius has received approvals for more than 70 clinical trials worldwide, with over 20 clinical trials being carried out in countries and regions including China, the European Union, the United States, Australia, the Philippines, Turkey, etc.
The year 2021 marks a year of comprehensive innovation and upgrade for Henlius, who has made continuous efforts in forming new drivers for growth through promoting R&D, production and business operation, said Zhang Wenjie, CEO of the company.
(Edited by Yu Huichen with Xinhua Silk Road, yhc0267@163.com)
A single purchase
